Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipotecan in advanced hepatocellular carcinoma
NCT02267213Phase 2Terminated
- Sponsor
- Taiwan Liposome Company
- Start
- Apr 2014
- Primary completion
- Jul 2015
- Modality
- Nanoparticles, Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of lipotecan in hepatocellular carcinoma (HCC), sponsored by Taiwan Liposome Company. Started Apr 2014; status: terminated.
02
Drugs
lipotecan
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02267213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02267213.